Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

February 10, 2025

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum